In:
Annals of the New York Academy of Sciences, Wiley, Vol. 1253, No. 1 ( 2012-04), p. 159-169
Abstract:
Glycobiology has contributed tremendously to the discovery and characterization of cancer‐related biomarkers containing glycans (i.e., glyco‐biomarkers) and a more detailed understanding of cancer biology. It is now recognized that most chronic diseases involve some elements of chronic inflammation; these include cancer, Alzheimer's disease, and metabolic syndrome (including consequential diabetes mellitus and cardiovascular diseases). By extending the knowledge and experience of the glycobiology community regarding cancer biomarker discovery, we should be able to contribute to the discovery of diagnostic/prognostic glyco‐biomarkers of other chronic diseases that involve chronic inflammation. Future integration of large‐scale “omics”‐type data (e.g., genomics, epigenomics, transcriptomics, proteomics, and glycomics) with computational model building, or a systems glycobiology approach, will facilitate such efforts.
Type of Medium:
Online Resource
ISSN:
0077-8923
,
1749-6632
DOI:
10.1111/nyas.2012.1253.issue-1
DOI:
10.1111/j.1749-6632.2012.06469.x
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2834079-6
detail.hit.zdb_id:
211003-9
detail.hit.zdb_id:
2071584-5
SSG:
11
Permalink